Immatics N.V. (IMTX) vs Odyssey Therapeutics (ODTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Immatics N.V. is the larger company by market cap ($878.6 million vs $815.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMTX | ODTX |
|---|---|---|
| Share price | $5.77 | $16.96 |
| Market cap | $878.58M | $815.23M |
| 1-day change | -3.03% | -7.52% |
| YTD return | -45.05% | — |
| 1-year return | -43.43% | — |
| 5-year return | -48.57% | — |
| EPS (TTM) | $-1.95 | $-6.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.41 | $29.05 |
| 52-week low | $5.72 | $15.10 |
| Distance from 52-week high | -53.51% | -41.62% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +176.78% | +104.42% |
| Average volume | 962.74K | 329.31K |
| Shares outstanding | 152.27M | 48.07M |
| Employees | 721 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Immatics N.V.
IMTX stock →Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 721 employees
About Odyssey Therapeutics
ODTX stock →Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptorassociated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 100 employees
IMTX vs ODTX FAQ
Which is bigger, Immatics N.V. or Odyssey Therapeutics?
Immatics N.V. (IMTX) is larger, with a market capitalization of $878.58M compared with $815.23M for Odyssey Therapeutics (ODTX).
Are Immatics N.V. and Odyssey Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.